Login to Your Account

Kiadis’ ATIR Boosts Long-term Survival in Phase I/II HSCT Trial

By Nuala Moran
Staff Writer

Wednesday, September 11, 2013
LONDON – Kiadis Pharma BV announced positive results in a five-year follow-up of the Phase I/II study of ATIR, a cell therapy for enabling hematopoietic stem cell transplants from non-identical donors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription